We were interested to read the recent article by van Baar and colleagues that described an open-label phase II trial of endoscopic duodenal mucosal resurfacing (DMR) in the management of patients with type 2 diabetes mellitus (T2DM).1 van Baar and colleagues demonstrated improvements in a number of parameters, most impressive of which was the reduction in haemoglobin A1c (HbA1c) at 12 months. It is intriguing to consider what the underlying mechanisms might be for this observed improvement in glycaemic control in patients with T2DM, what confounders might be at play and how these might inform the design of future sham-controlled studies. For example, the investigators comment that the initial weight loss ~2.3 kg observed in …

中文翻译：

---

十二指肠黏膜表面置换后 2 型糖尿病患者 HbA1c 的降低：其他因素是否在起作用？

我们有兴趣阅读 van Baar 及其同事最近发表的文章，该文章描述了内窥镜十二指肠黏膜表面置换 (DMR) 治疗 2 型糖尿病 (T2DM) 患者的开放标签 II 期试验。1 van Baar 及其同事证明许多参数的改善，其中最令人印象深刻的是 12 个月时血红蛋白 A1c (HbA1c) 的减少。考虑观察到的 T2DM 患者血糖控制改善的潜在机制可能是什么，可能有哪些混杂因素在起作用，以及这些可能如何影响未来假对照研究的设计，这很有趣。例如，研究人员评论说，在……中观察到的初始体重减轻了约 2.3 公斤。